{"transactions":[{"id":1013834,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-10-24T20:00:12.000Z","date":"2025-10-23","kind":"sale","planned":false,"acquired":false,"shares":967,"price":0.82,"value":792.94,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 28,906 unvested RSUs."}],"balance_after":28906,"source":{"system":"sec-edgar","filing":"0001710969-25-000003","document":"form4-10242025_081007.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000171096925000003/form4-10242025_081007.xml","form_type":"4"}},{"id":1013833,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-10-24T20:00:12.000Z","date":"2025-10-22","kind":"sale","planned":false,"acquired":false,"shares":32230,"price":0.83,"value":26750.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 28,906 unvested RSUs."}],"balance_after":29873,"source":{"system":"sec-edgar","filing":"0001710969-25-000003","document":"form4-10242025_081007.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000171096925000003/form4-10242025_081007.xml","form_type":"4"}},{"id":1101076,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-06-26T20:00:16.000Z","date":"2025-06-24","kind":"sale","planned":false,"acquired":false,"shares":3631,"price":4.01,"value":14560.31,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.87 to $4.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 28,906 unvested RSUs."}],"balance_after":62100,"source":{"system":"sec-edgar","filing":"0001415889-25-018320","document":"form4-06262025_080607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588925018320/form4-06262025_080607.xml","form_type":"4"}},{"id":1122961,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-06-04T20:00:15.000Z","date":"2025-06-03","kind":"sale","planned":false,"acquired":false,"shares":2850,"price":3.74,"value":10659.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.52 to $4.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 40,953 unvested RSUs."}],"balance_after":65731,"source":{"system":"sec-edgar","filing":"0001415889-25-015680","document":"form4-06042025_080607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588925015680/form4-06042025_080607.xml","form_type":"4"}},{"id":1308109,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-07T20:12:29.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":45200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on January 6, 2025 and vests over four years beginning on the vesting commencement date of January 6, 2025, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 6, 2029, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":45200,"derivative":{"exercise_price":7.53,"expiration_date":"2035-01-05","underlying":"Common Stock","underlying_shares":45200},"source":{"system":"sec-edgar","filing":"0001415889-25-001059","document":"form4-01082025_010125.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588925001059/form4-01082025_010125.xml","form_type":"4"}},{"id":1308108,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-07T20:12:29.000Z","date":"2025-01-06","kind":"sale","planned":false,"acquired":false,"shares":1706,"price":7.63,"value":13016.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.48 to $7.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 49,523 unvested RSUs."}],"balance_after":68581,"source":{"system":"sec-edgar","filing":"0001415889-25-001059","document":"form4-01082025_010125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588925001059/form4-01082025_010125.xml","form_type":"4"}},{"id":1308107,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-07T20:12:29.000Z","date":"2025-01-06","kind":"grant","planned":false,"acquired":true,"shares":10100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 6, 2026, as to 1/3 of the shares underlying the RSUs on January 6, 2027 and as to the final 1/3 of shares underlying the RSUs on January 6, 2028."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 49,523 unvested RSUs."}],"balance_after":70287,"source":{"system":"sec-edgar","filing":"0001415889-25-001059","document":"form4-01082025_010125.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588925001059/form4-01082025_010125.xml","form_type":"4"}},{"id":1468164,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-06-27T20:00:09.000Z","date":"2024-06-26","kind":"sale","planned":false,"acquired":false,"shares":4163,"price":4.75,"value":19774.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on June 22, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.50 to $5.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 44,131 unvested RSUs."}],"balance_after":60187,"source":{"system":"sec-edgar","filing":"0001415889-24-018375","document":"form4-06272024_080606.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588924018375/form4-06272024_080606.xml","form_type":"4"}},{"id":1495204,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-06-03T20:00:12.000Z","date":"2024-05-31","kind":"sale","planned":false,"acquired":false,"shares":1786,"price":6.09,"value":10876.74,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units (\"RSUs\") granted on May 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 56,177 unvested RSUs."}],"balance_after":64350,"source":{"system":"sec-edgar","filing":"0001415889-24-015224","document":"form4-06032024_080608.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588924015224/form4-06032024_080608.xml","form_type":"4"}},{"id":1685540,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2024-01-05T16:04:02.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on January 4, 2024 and vests over four years beginning on the vesting commencement date of January 4, 2024, with 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter until January 4, 2028, subject to the Reporting Person's continued employment with the Issuer."}],"balance_after":20500,"derivative":{"exercise_price":7,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001415889-24-000767","document":"form4-01052024_090154.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588924000767/form4-01052024_090154.xml","form_type":"4"}},{"id":1685539,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-01-05T16:04:02.000Z","date":"2024-01-04","kind":"sale","planned":false,"acquired":false,"shares":1227,"price":6.74,"value":8269.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's RSUs granted on January 4, 2023 and January 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.73 to $6.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 61,831 unvested RSUs."}],"balance_after":66136,"source":{"system":"sec-edgar","filing":"0001415889-24-000767","document":"form4-01052024_090154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588924000767/form4-01052024_090154.xml","form_type":"4"}},{"id":1685538,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-01-05T16:04:02.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":4600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with the Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2025, as to 1/3 of the shares underlying the RSUs on January 4, 2026 and as to the final 1/3 of shares underlying the RSUs on January 4, 2027."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 65,156 unvested RSUs."}],"balance_after":67363,"source":{"system":"sec-edgar","filing":"0001415889-24-000767","document":"form4-01052024_090154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588924000767/form4-01052024_090154.xml","form_type":"4"}},{"id":1845250,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T20:00:21.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":48192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 22, 2023 and vests over four years beginning on the vesting commencement date of June 22, 2023, with 25% of the shares underlying the option vesting on June 22, 2024, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter."}],"balance_after":48192,"derivative":{"exercise_price":14.56,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":48192},"source":{"system":"sec-edgar","filing":"0001415889-23-010285","document":"form4-06232023_080610.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588923010285/form4-06232023_080610.xml","form_type":"4"}},{"id":1845249,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-06-23T20:00:21.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":36144,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's Amended and Restated 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on June 22, 2024, as to 1/3 of the shares underlying the RSUs on June 22, 2025 and as to the final 1/3 of shares underlying the RSUs on June 22, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 60,556 unvested RSUs."}],"balance_after":62763,"source":{"system":"sec-edgar","filing":"0001415889-23-010285","document":"form4-06232023_080610.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588923010285/form4-06232023_080610.xml","form_type":"4"}},{"id":1870022,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:00:40.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":648,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The canceled option was granted on January 3, 2022 and provided for the purchase of up to 1,620 shares of common stock of the issuer based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters, of which, prior to the option exchange program, options to purchase 432 shares had vested, options to purchase 864 shares had been forfeited and options to purchase up to 324 shares were unvested assuming maximum level of achievement (options to purchase 216 shares were unvested assuming target level of achievement). The vested portion of the option and the unvested portion of the option assuming target level of achievement were eligible for the issuer's option exchange program."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":68.5,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":648},"source":{"system":"sec-edgar","filing":"0001415889-23-009136","document":"form4-06022023_080614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588923009136/form4-06022023_080614.xml","form_type":"4"}},{"id":1870021,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:00:40.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3059,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The canceled option was granted on January 3, 2022 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":68.5,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":3059},"source":{"system":"sec-edgar","filing":"0001415889-23-009136","document":"form4-06022023_080614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588923009136/form4-06022023_080614.xml","form_type":"4"}},{"id":1870020,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:00:40.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1813,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The canceled option was granted on January 4, 2021 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":343,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":1813},"source":{"system":"sec-edgar","filing":"0001415889-23-009136","document":"form4-06022023_080614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588923009136/form4-06022023_080614.xml","form_type":"4"}},{"id":1870019,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:00:40.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2399,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The canceled option was granted on January 2, 2020 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":192,"expiration_date":"2030-01-01","underlying":"Common Stock","underlying_shares":2399},"source":{"system":"sec-edgar","filing":"0001415889-23-009136","document":"form4-06022023_080614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588923009136/form4-06022023_080614.xml","form_type":"4"}},{"id":1870018,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:00:40.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2999,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The canceled option was granted on January 2, 2019 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":259.5,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":2999},"source":{"system":"sec-edgar","filing":"0001415889-23-009136","document":"form4-06022023_080614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588923009136/form4-06022023_080614.xml","form_type":"4"}},{"id":1870017,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:00:40.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1399,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The canceled option was granted on February 7, 2018 and provided for vesting with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":643,"expiration_date":"2028-02-06","underlying":"Common Stock","underlying_shares":1399},"source":{"system":"sec-edgar","filing":"0001415889-23-009136","document":"form4-06022023_080614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588923009136/form4-06022023_080614.xml","form_type":"4"}},{"id":1870016,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:00:40.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":578,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The canceled option was granted on July 19, 2017 and provided for vesting over four years with 1/48th of the shares underlying the option vested on August 31, 2017 and an additional 1/48th of the shares vested at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":750,"expiration_date":"2027-07-18","underlying":"Common Stock","underlying_shares":578},"source":{"system":"sec-edgar","filing":"0001415889-23-009136","document":"form4-06022023_080614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588923009136/form4-06022023_080614.xml","form_type":"4"}},{"id":1870015,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-02T20:00:40.000Z","date":"2023-05-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1841,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The canceled option was granted on June 17, 2016 and provided for vesting over four years with 1/48th of the shares underlying the option vested on April 8, 2015 and an additional 1/48th of the shares vested at the end of each successive one-month period thereafter."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares and exercise price reflect a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":0,"derivative":{"exercise_price":167,"expiration_date":"2025-06-17","underlying":"Common Stock","underlying_shares":1841},"source":{"system":"sec-edgar","filing":"0001415889-23-009136","document":"form4-06022023_080614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588923009136/form4-06022023_080614.xml","form_type":"4"}},{"id":1870014,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-06-02T20:00:40.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":14736,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 31, 2023, the issuer canceled, pursuant to the issuer's option exchange program, all outstanding unexercised options granted to the reporting person. In exchange, the reporting person received (i) in the case of the canceled options that were fully vested, a grant of 11,313 restricted stock units (the \"RSUs\") that vest over two years, with 50% of such RSUs vesting on\nMay 31, 2024 and 50% of such RSUs vesting on May 31, 2025 and (ii) in the case of the canceled options that were unvested, a grant of 3,423 RSUs that vest over three years, with 85% of such RSUs vesting on May 31, 2025 and 15% of such RSUs vesting on May 31, 2026, in each case, subject to the reporting person's continued service with the issuer. Each RSU represents a contingent right to receive one share of the issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 24,412 unvested RSUs."}],"balance_after":26619,"source":{"system":"sec-edgar","filing":"0001415889-23-009136","document":"form4-06022023_080614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588923009136/form4-06022023_080614.xml","form_type":"4"}},{"id":1952254,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-15T20:00:18.000Z","date":"2023-03-14","kind":"grant","acquired":true,"shares":432,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 3, 2022, the Reporting Person was granted an option to purchase up to 1,620 shares of common stock of the Issuer. Specified portions of the options vest based on the level of achievement of specified performance metrics relating to financial, operational and scientific matters."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 14, 2023, the Compensation Committee of the Issuer's Board of Directors determined that certain of the performance conditions were achieved at specific levels of achievement, resulting in vesting of the option as to 432 shares of common stock. The Compensation Committee has made no determination with respect to certain performance metrics, which could result in the further vesting of up to 324 shares of common stock underlying the option."}],"balance_after":432,"derivative":{"exercise_price":68.5,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":432},"source":{"system":"sec-edgar","filing":"0001415889-23-004976","document":"form4-03152023_080310.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588923004976/form4-03152023_080310.xml","form_type":"4"}},{"id":2060535,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-01-06T20:00:33.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":60,"price":28.54,"value":1712.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units (\"RSUs\") granted on January 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.52 to $28.71, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 9,676 unvested RSUs."}],"balance_after":11883,"source":{"system":"sec-edgar","filing":"0001415889-23-000639","document":"form4-01062023_080117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588923000639/form4-01062023_080117.xml","form_type":"4"}},{"id":2060534,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2023-01-06T20:00:33.000Z","date":"2023-01-04","kind":"grant","acquired":true,"shares":9525,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 9,827 unvested RSUs."}],"balance_after":11943,"source":{"system":"sec-edgar","filing":"0001415889-23-000639","document":"form4-01062023_080117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588923000639/form4-01062023_080117.xml","form_type":"4"}},{"id":2130394,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-10-28T16:15:32.000Z","date":"2022-10-26","kind":"sale","acquired":false,"shares":194,"price":6.51,"value":1262.94,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units (\"RSUs\") granted on June 25, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.51 to $6.56, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 302 unvested RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The number of shares of common stock reported on this Form 4 reflects a 1-for-50 reverse stock split effected by the Issuer on October 20, 2022."}],"balance_after":2418,"source":{"system":"sec-edgar","filing":"0001415889-22-010880","document":"form4-10282022_041020.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588922010880/form4-10282022_041020.xml","form_type":"4"}},{"id":2219380,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-06-29T20:12:12.000Z","date":"2022-06-27","kind":"sale","acquired":false,"shares":2613,"price":0.37,"value":966.81,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 45,611 unvested RSUs."}],"balance_after":130595,"source":{"system":"sec-edgar","filing":"0001415889-22-007062","document":"form4-06292022_050657.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588922007062/form4-06292022_050657.xml","form_type":"4"}},{"id":2444092,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T20:00:37.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":153000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on January 3, 2022 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."}],"balance_after":153000,"derivative":{"exercise_price":1.37,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":153000},"source":{"system":"sec-edgar","filing":"0001415889-22-000405","document":"form4-01052022_080127.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588922000405/form4-01052022_080127.xml","form_type":"4"}},{"id":2444091,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2022-01-05T20:00:37.000Z","date":"2022-01-04","kind":"sale","acquired":false,"shares":2850,"price":1.3,"value":3705.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units granted on January 4, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.25 to $1.39, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 53,611 unvested RSUs."}],"balance_after":133208,"source":{"system":"sec-edgar","filing":"0001415889-22-000405","document":"form4-01052022_080127.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588922000405/form4-01052022_080127.xml","form_type":"4"}},{"id":2532808,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2021-10-28T20:04:51.000Z","date":"2021-10-26","kind":"sale","acquired":false,"shares":9449,"price":1.8,"value":17008.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units (\"RSUs\") granted on June 25, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.79 to $1.89, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 61,166 unvested RSUs."}],"balance_after":136058,"source":{"system":"sec-edgar","filing":"0001415889-21-005012","document":"form4-10282021_051034.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588921005012/form4-10282021_051034.xml","form_type":"4"}},{"id":2651819,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2021-06-29T17:26:10.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":2452,"price":5.77,"value":14148.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the reporting person's restricted stock units granted on June 25, 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 91,666 unvested RSUs."}],"balance_after":145507,"source":{"system":"sec-edgar","filing":"0001415889-21-003259","document":"form4-06292021_050653.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000141588921003259/form4-06292021_050653.xml","form_type":"4"}},{"id":2920998,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-05T16:48:47.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":90667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on January 4, 2021 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."}],"balance_after":90667,"derivative":{"exercise_price":6.86,"expiration_date":"2031-01-03","underlying":"Common Stock","underlying_shares":90667},"source":{"system":"sec-edgar","filing":"0001179110-21-000166","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911021000166/edgar.xml","form_type":"4"}},{"id":2920997,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-01-05T16:48:47.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":22666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2022, as to 1/3 of the shares underlying the RSUs on January 4, 2023 and as to the final 1/3 of shares underlying the RSUs on January 4, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 99,666 unvested RSUs."}],"balance_after":147959,"source":{"system":"sec-edgar","filing":"0001179110-21-000166","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911021000166/edgar.xml","form_type":"4"}},{"id":2998703,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-10-28T20:22:55.000Z","date":"2020-10-26","kind":"grant","acquired":true,"shares":61000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 25, 2020, the reporting person was granted performance-based restricted stock unit (\"RSUs\") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with the Issuer, the RSUs will vest as to 50% of the shares underlying the RSUs on October 26, 2021, the first anniversary of the achievement of the performance condition, and as to the remaining 50% of the shares underlying the RSUs on October 26, 2022, the second anniversary of the achievement of the performance condition."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 77,000 unvested RSUs."}],"balance_after":125293,"source":{"system":"sec-edgar","filing":"0001179110-20-010706","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911020010706/edgar.xml","form_type":"4"}},{"id":3097627,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-06-29T21:56:42.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Grant of restricted stock units (\"RSUs\") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with the Issuer, the RSUs will vest as to 50% of the shares underlying the RSUs on June 25, 2021 and the remaining 50% of the shares underlying the RSUs on June 25, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 16,000 unvested RSUs."}],"balance_after":64293,"source":{"system":"sec-edgar","filing":"0001104659-20-078328","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000110465920078328/a4.xml","form_type":"4"}},{"id":3113469,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-11T16:58:42.000Z","date":"2020-06-09","kind":"exercise","acquired":false,"shares":11520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":2.3,"expiration_date":"2024-10-01","underlying":"Common Stock","underlying_shares":11520},"source":{"system":"sec-edgar","filing":"0001179110-20-007239","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911020007239/edgar.xml","form_type":"4"}},{"id":3113468,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-11T16:58:42.000Z","date":"2020-06-09","kind":"exercise","acquired":false,"shares":15360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":2.3,"expiration_date":"2024-12-03","underlying":"Common Stock","underlying_shares":15360},"source":{"system":"sec-edgar","filing":"0001179110-20-007239","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911020007239/edgar.xml","form_type":"4"}},{"id":3113467,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-11T16:58:42.000Z","date":"2020-06-09","kind":"exercise","acquired":false,"shares":5077,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.21,"expiration_date":"2025-10-01","underlying":"Common Stock","underlying_shares":5077},"source":{"system":"sec-edgar","filing":"0001179110-20-007239","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911020007239/edgar.xml","form_type":"4"}},{"id":3113466,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-06-11T16:58:42.000Z","date":"2020-06-09","kind":"exercise","acquired":false,"shares":11520,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":2.3,"expiration_date":"2024-10-01","underlying":"Common Stock","underlying_shares":11520},"source":{"system":"sec-edgar","filing":"0001179110-20-007239","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911020007239/edgar.xml","form_type":"4"}},{"id":3113465,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-06-11T16:58:42.000Z","date":"2020-06-09","kind":"exercise","acquired":true,"shares":11520,"price":2.3,"value":26496.0,"ownership":{"direct":true},"balance_after":48293,"source":{"system":"sec-edgar","filing":"0001179110-20-007239","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911020007239/edgar.xml","form_type":"4"}},{"id":3113464,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-06-11T16:58:42.000Z","date":"2020-06-09","kind":"exercise","acquired":true,"shares":15360,"price":2.3,"value":35328.0,"ownership":{"direct":true},"balance_after":36773,"source":{"system":"sec-edgar","filing":"0001179110-20-007239","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911020007239/edgar.xml","form_type":"4"}},{"id":3113463,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-06-11T16:58:42.000Z","date":"2020-06-09","kind":"exercise","acquired":true,"shares":5077,"price":5.21,"value":26451.17,"ownership":{"direct":true},"balance_after":21413,"source":{"system":"sec-edgar","filing":"0001179110-20-007239","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911020007239/edgar.xml","form_type":"4"}},{"id":3113462,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2020-06-11T16:58:42.000Z","date":"2020-06-09","kind":"exercise","acquired":true,"shares":11520,"price":2.3,"value":26496.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 4,816  shares acquired under the Issuer's Amended and Restated 2017 Employee Stock Purchase Plan on June 28, 2019."}],"balance_after":16336,"source":{"system":"sec-edgar","filing":"0001179110-20-007239","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911020007239/edgar.xml","form_type":"4"}},{"id":3323472,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-01-03T16:11:53.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 2, 2020 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."}],"balance_after":120000,"derivative":{"exercise_price":3.84,"expiration_date":"2030-01-01","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001179110-20-000156","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911020000156/edgar.xml","form_type":"4"}},{"id":3704303,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-04T17:00:25.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on January 2, 2019 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."}],"balance_after":150000,"derivative":{"exercise_price":5.19,"expiration_date":"2029-01-01","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001179110-19-000455","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911019000455/edgar.xml","form_type":"4"}},{"id":4068723,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2018-02-09T16:30:30.000Z","date":"2018-02-07","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 7, 2018 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter."}],"balance_after":70000,"derivative":{"exercise_price":12.86,"expiration_date":"2028-02-06","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001179110-18-001889","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911018001889/edgar.xml","form_type":"4"}},{"id":4253316,"issuer":{"id":7964,"kind":"organization","name":"KALA BIO, Inc."},"owners":[{"id":73971,"kind":"person","name":"Reumuth Mary","position":1,"cik":"0001710969","reported_name":"Reumuth Mary","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-07-21T16:19:40.000Z","date":"2017-07-19","kind":"grant","acquired":true,"shares":28973,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted, effective on July 19, 2017 and vests over four years, with 2.0833% of the shares underlying the option vesting on August 31, 2017 and an additional 2.0833% of the shares vesting at the end of each successive one-month period thereafter."}],"balance_after":28973,"derivative":{"exercise_price":15,"expiration_date":"2027-07-18","underlying":"Common Stock","underlying_shares":28973},"source":{"system":"sec-edgar","filing":"0001179110-17-010591","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1710969/000117911017010591/edgar.xml","form_type":"4"}}]}